LY3463251 / Eli Lilly - LARVOL DELTA

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist. (PubMed, Cell Metab) - P1 | "A subsequent 12-week multiple ascending dose study in overweight and obese participants showed that LY3463251 induced significant decreases in food intake and appetite scores associated with modest body weight reduction independent of nausea and emesis (clinicaltrials.gov: NCT03764774). These observations demonstrate that agonism of the GFRAL/RET system can modulate energy balance in humans, though the decrease in body weight is surprisingly modest, suggesting challenges in leveraging the GDF15 system for clinical weight-loss applications."

Journal • Genetic Disorders • Obesity • GDF15

A Study of LY3463251 in Healthy Participants (clinicaltrials.gov) - P1; N=118; Terminated; Sponsor: Eli Lilly and Company; Trial completion date: Apr 2021 ➔ Dec 2020; Recruiting ➔ Terminated; Trial primary completion date: Apr 2021 ➔ Dec 2020; Trial was terminated due to an insufficient benefit/tolerability ratio

Clinical • Trial completion date • Trial primary completion date • Trial termination • Obesity

A Study of LY3463251 in Healthy Participants (clinicaltrials.gov) - P1; N=143; Recruiting; Sponsor: Eli Lilly and Company; Suspended ➔ Recruiting; Trial completion date: Dec 2020 ➔ Apr 2021; Trial primary completion date: Dec 2020 ➔ Apr 2021

Clinical • Enrollment open • Trial completion date • Trial primary completion date • Obesity

A Study of LY3463251 in Healthy Participants (clinicaltrials.gov) - P1; N=143; Suspended; Sponsor: Eli Lilly and Company; Trial completion date: Sep 2020 ➔ Dec 2020; Recruiting ➔ Suspended; Trial primary completion date: Sep 2020 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date • Trial suspension • Metabolic Disorders • Obesity